
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39294186
67769
10.1038/s41598-024-67769-1
Article
Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes
Rabin Alexandra 1
Bello Elisa 1
Kumar Saurabh 1
Zeki Dalia Abou 1
Afshari Khashayar 2
Deshpande Mugdha 1
Francis Nimmy 1
Khalighinejad Farnaz 1
Umeton Raffaella 1
Radu Irina 1
Qutab Fatima 1
Kwong Danny 1
Kurban Mariana 1
Hemond Christopher 1
Richmond Jillian M. Jillian.Richmond@umassmed.edu

12
Ionete Carolina Carolina.Ionete@umassmed.edu

1
1 https://ror.org/0464eyp60 grid.168645.8 0000 0001 0742 0364 Department of Neurology, UMass Chan Medical School, Worcester, MA USA
2 https://ror.org/0464eyp60 grid.168645.8 0000 0001 0742 0364 Department of Dermatology, UMass Chan Medical School, Worcester, MA USA
18 9 2024
18 9 2024
2024
14 2179321 4 2024
12 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Multiple sclerosis (MS) is an inflammatory demyelinating disease with heterogeneous clinical presentations and variable long-term disability accumulation. There are currently no standard criteria to accurately predict disease outcomes. In this study we investigated the cross-sectional relationship between disease phenotype and immune-modulating cytokines and chemokines in cerebrospinal fluid (CSF). We analyzed CSF from 20 DMT-naïve MS patients using Olink Proteomics’ Target 96 Inflammation panel and correlated the resulting analytes with respect to (1) disease subtype, (2) patient age and sex, (3) extent of clinical disability, and (4) MRI segmental brain volumes. We found that intrathecal IL-4 correlated with higher Expanded Disability Status Scale (EDSS) scores and longer 25-foot walk times, and CD8A correlated with decreased thalamic volumes and longer 9-hole peg test times. Male sex was associated with higher FGF-19 expression, and Tumefactive MS with elevated CCL4. Several inflammatory markers were correlated with older age at the time of LP. Finally, higher intrathecal IL-33 correlated with increased MS lesion burden and multi-compartment brain atrophy. This study confirms immune heterogeneity underlying CSF profiles in MS, but also identifies several inflammatory protein biomarkers that may be of use for predicting clinical outcomes in future algorithms.

Keywords

Multiple sclerosis (MS)
Targeted proteomics
Cerebrospinal fluid (CSF)
Expanded Disability Status Scale (EDSS)
Age
Subject terms

Multiple sclerosis
Prognostic markers
2020 Consortium of Multiple Sclerosis Centers (CMSC) Medical Student Research Scholarship2022 CMSC Medical Student Research Scholarship2021 CMSC Medical Student Research ScholarshipSPARK grant from the UMass Center for Clinical and Translational Sciencegrant #UL1-TR001453 Afshari Khashayar SPARK grant from the UMass Center for Clinical and Translational Sciencegrant #UL1-TR001453 Richmond Jillian M. issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Multiple sclerosis (MS) is an immune-mediated, chronic neurological disease and a leading cause of disability in young patients1. The clinical course of MS is heterogenous and difficult to predict, with a wide range of symptomatic manifestations between individuals2. Patient phenotypes include clinically isolated, radiologically isolated, relapsing–remitting, primary or secondary progressive, or progressive-relapsing MS, with a broad spectrum of disease severity within this framework1. Other phenotypic classifications have been proposed including clinically isolated syndrome versus relapsing–remitting disease or progressive disease further stratified by active or inactive disease within the past 12 months3.

While clinicians are guided by the McDonald criteria in establishing a diagnosis, several common syndromes often masquerade as MS and misdiagnoses do occur. In one 2016 study by Solomon et al. following 110 patients with an incorrect MS diagnosis, 33% held this misdiagnosis for 10 years or longer, and 31% experienced “unnecessary morbidity as a direct result” of their misdiagnosis according to neurologist assessment, in part due to the consequences of immunotherapy or corticosteroid use4. Although the McDonald criteria were revised in 2017, interrater variability in patient assessment persists, suggesting further opportunities to improve the reliability of MS diagnoses5.

MRI is currently the most important paraclinical tool for MS diagnosis and observation6. Cerebrospinal fluid (CSF) immunoglobulin G analysis and clinical outcome measures (expanded disability status scale, nine-hole peg test, symbol digit modality test, and timed 25-foot walk) are several avenues, among others, available to establish a diagnosis and quantify disease severity7,8. Additionally, the presence of oligoclonal bands and low levels of vitamin D have been shown to portend conversion from clinically isolated syndrome to clinically definite MS9,10. Despite these tools, there are currently no standard criteria to comprehensively measure disease progression or predict clinical phenotype. Identification of additional biomarkers could allow us to better classify and treat newly diagnosed MS patients11. This approach fits within the framework of personalized medicine, a concept postulated to represent the future of neurologic treatment as a less expensive and more effective approach to MS patient care.

Since it bathes all CNS structures, cerebrospinal fluid offers a more direct approximation of cellular activity within the central nervous system than does peripheral blood12. Here, we performed an exploratory analysis of CSF immune protein expression in a cohort of Disease Modifying Therapy (DMT)-naïve MS patients. We chose a commercially available high throughput panel of 92 immunologic analytes encompassing cytokines and markers of cells with known roles in MS pathogenesis, including IL-12, IFNγ, TNF, CD40, and CD8, as well as exploratory proteins without an established role in MS (FGF-19). We aimed to determine relationships between these intrathecal immune proteins and a variety of clinical and radiographic measures relevant to MS phenotypic expression and disease severity. We chose a hypothesis-generating approach in an effort to better understand the underlying immune expression pathways associated with MS pathophysiology.

Results

Cohort description

Fifteen relapsing remitting MS (RRMS) and 5 progressive MS (PMS) patients were included (see patient data in Table 1). Mean age was 42.4 ± 13.7 (SD). Fifteen patients (75%) were female. Mean EDSS (available for 14 patients) was 2.6 ± 1.4, with a median IQR of 2.25 (2.0, 3.0). Of these, one RRMS patient was classified as having “inactive” disease demonstrated by meeting No Evidence of Disease Activity- 3 (NEDA-3) criteria in the past 12 months from LP, defined by (1) no clinical relapses, (2) no progression of EDSS within 6 months, and (3) no radiographic progression on brain MRI (Lu et al. 2018). The remaining 19 patients were considered to have “active” disease, not meeting NEDA-3 within 12 months prior to LP. Additionally, 2 RRMS patients with active disease were diagnosed with Tumefactive features and were subsequently designated in the following analyses as having Tumefactive MS. Table 1 Patient characteristics and clinical information.

Patient	Sex	Age at LP	Diagnosis	Activity	EDSS	25-foot walk	9-hole peg	SDMT	
A	Female	32	RRMS	Inactive	1	5.1	13.3	66	
B	Female	64	RRMS	Active	–	5.47	13.16	49	
C	Female	26	RRMS	Active	1.5	4.72	12.8	63	
D	Female	51	RRMS	Active	–	4.8	9.8	59	
E	Female	39	RRMS	Active	–	6	12.5	39	
F	Female	65	RRMS	Active	–	4.04	9.73	61	
G	Male	49	RRMS	Active	3	7.78	14.3	68	
H	Female	25	RRMS	Active	2	6.13	10.13	51	
I	Female	39	RRMS	Active	–	5.59	12.6	57	
J	Male	28	RRMS	Active	1	3.2	19.6	65	
K	Male	26	RRMS	Active	3	5.3	15.6	41	
L	Female	26	RRMS	Active	2.5	6.4	27.5	46	
M	Female	41	RRMS	Active	2	2.7	12.5	65	
N	Female	47	Tumefactive	Active	–	–	–	–	
O	Female	34	Tumefactive	Active	2	3.81	13.75	48	
P	Female	46	PMS	Active	2	5.31	10.41	62	
Q	Male	61	PMS	Active	3.5	4.75	13.37	41	
R	Male	65	PMS	Active	2.5	4.85	17.5	38	
S	Female	44	PMS	Active	6.5	12.6	16.78	36	
T	Female	35	PMS	Active	4	8.1	15.1	57	
LP lumbar puncture, EDSS Expanded Disability Status Scores, SDMT Symbol Digit Modalities Test, RRMS relapsing remitting multiple sclerosis, PMS progressive multiple sclerosis.

Intrathecal immune correlates of clinical disability

CSF, brain MRI, and clinical metrics were collected and analyzed (Fig. 1A). Several intrathecal immune proteins correlated with higher clinical disability (Fig. 1B). Positive correlations were observed between intrathecal IL-4 and Expanded Disability Status Scale (EDSS) or 25-foot walk time (25-FWT), as well as between CD8A and 9-hole peg test (9HPT) (Fig. 1C–E). A significant negative6 correlation existed between Single Digit Modalities Test (SDMT) score and each of the following analytes: CD244, OPG, SCF, Flt3L and 4E-BP1 (Fig. 1F–J).Figure 1 CSF protein correlates of clinical status in MS patients. (A) Study overview. This image was created with BioRender.com (B) Pearson correlation matrix of clinical disability scores and normalized protein expression values from Olink Target 96 Inflammation panel. (C) IL4 correlates with EDSS (note: EDSS within 8 months of lumbar puncture available for n = 14 patients). (D) IL4 correlates with 25-foot walk. (E) CD8A correlates with 9-hole peg test. (F) CD244, (G) OPG, (H) SCF, (I) Flt3L and (J) 4E-BP1 correlate with poorer SDMT performance (n = 20 DMT-naïve MS patients).

Intrathecal immune correlates of age

The following immune proteins were positively correlated with age at the time of lumbar puncture: CDCP1, IL7, TWEAK, CASP8, LIF, LIFR, LAP TGF-beta-1, HGF, PD-L1, and OPG (Fig. 2A–J). In contrast, IL-13 was negatively correlated with patient age (Fig. 2K).Figure 2 Intrathecal cytokines associated with age of MS patients at time of Lumbar Puncture. (A) CDCP1, (B) IL7, (C) TWEAK, (D) CASP8, (E) LIF, (F) LIFR, (G) LAP TGF-beta-1, (H) HGF, (I) PD-L1, and (J) OPG increased in greater age. (K) IL-13 was lower in older patients. (n = 20 MS patients).

Immune analytes differ by MS subtype and patient sex

Next, intrathecal analytes were compared across disease subtype and biological sex. Male sex was associated with higher FGF19 (Fig. 3A–C,G). Amongst patients with RRMS, female patients had higher IL-10RA and IL-20 than male patients (Fig. 3B,H,I). These differences persisted when accounting for age (supplemental Tables 4a–4c, supplemental Fig. 3). No differences were identified between relapsing remitting and progressive MS subtypes (Fig. 3D). Tumefactive MS exhibited higher CCL4 than their non-Tumefactive counterparts. (Fig. 3E,J). No inflammatory analytes were specific to RRMS (Fig. 3F).Figure 3 Intrathecal cytokines differ by clinical subtype and male/female sex. (A–C) Volcano plots comparing male versus female sex across disease subtypes for (A) all patients, (B) only amongst patients with RRMS, and (C) only patients with PMS. Adjusted p values are as follows: (A) Full cohort: FGF-19 p = 0.0003 (B) RRMS: FGF-19 p = 0.02; IL-10RA p = 0.02; IL-20 p = 0.02 (C) PMS: FGF-19 p = 0.07. (D–F) Volcano plots comparing cytokines across disease subtype. Adjusted p values are as follows: (D) RRMS vs PMS: SLAMF1 p = 0.97 (E) Tumefactive MS vs Other: CCL4 p = 0.02. (F) RRMS vs Other was ns. Panels A–F were calculated using Olink’s volcano plot software. A red data point reflects significance (p < 0.05) after adjusting for multiple testing via Benjamini-Hochberg method. Dotted line indicates significance (p < 0.05) prior to adjusting for multiple testing. (G–J) Analysis of protein biomarkers identified in volcano plots by sex and disease subtypes. (G) FGF-19, (H) IL-10RA and (I) IL-20 expression in males versus females grouped as all patients, RRMS or PMS as indicated. (J) CCL4 expression in tumefactive versus other subtypes. Panels G–J were calculated using unpaired 2-tailed t tests as indicated (*p < 0.05, **p < 0.01, ***p < 0.001). Full cohort: n = 20; RRMS: n = 13; PMS: n = 5; Tumefactive: n = 2. Please refer to Supplemental Tables 1 and 2 for a comprehensive list of analytes and p values.

Intrathecal immune correlates of brain segmental volumes by MRI

Immune biomarkers were then compared against volumetric MRI features (Fig. 4). IL-33 was negatively correlated with cortical gray matter (p = 0.02), total gray matter (p = 0.02), thalamic volume (p = 0.049), and caudate volume (p = 0.01) (Fig. 4A–E). IL-33 was positively correlated with total lesion volume (p = 0.03) and ventricular size (p = 0.03) (Fig. 4C & F). Intrathecal CD8a negatively correlated with thalamic (p = 0.03) and caudate volumes (p = 0.04) (Fig. 4G). Older age correlated with decreased gray matter (p = 0.03) and increased ventricular size (vCSF) (p = 0.008). Finally, greater T2 FLAIR lesion volume predicted increased ventricular size (p = 0.002) (supplemental Fig. 1). A comprehensive list of significant associations between protein analytes and MRI brain volumes can be found in supplemental Table 5.Figure 4 MRI features correlate with Inflammatory biomarkers. (A–F) Intrathecal IL-33 versus segmental brain volume measurements as follows: (A) cortical gray matter, (B) total gray matter, (C) ventricular CSF volume, (D) thalamic volume, (E) caudate volume, and (F) lesion volume (T2LV). (G) Intrathecal CD8A versus thalamic (blue) and caudate (purple) volumes. X-axis values are normalized protein concentrations (NPX values) per Olink analysis. (n = 17 MS patients for whom MRI data was available).

Clinical disability scores correlate with MRI features

Finally, brain volumes on MRI were compared against clinical disability (Fig. 5). SDMT was negatively correlated with total lesion volume and ventricular size (Fig. 5A,B), and positively correlated with thalamic volume (Fig. 5C). There was no significant association between segmental brain volumes and the other clinical metrics of disability included in this study (supplemental Fig. 2).Figure 5 MRI features correlate with Clinical Metrics of Disability. (A–C) SDMT versus segmental brain volume measurements as follows: (A) T2 FLAIR lesion volume, (B) ventricular volume, and (C) thalamic volume. (n = 17 MS patients for whom MRI data was available).

Discussion

The goal of this study was to identify CSF immune biomarkers of clinical and MRI phenotypes in Multiple Sclerosis (MS). Our study approach is comparable to a recent investigation by Huang et al. who also employed Olink to examine plasma and CSF biomarkers with the goal of distinguishing healthy from MS for diagnostic purposes13. Our study, however, comprised a cohort of only DMT-naïve MS patients with a focus on stratification of various phenotypic presentations within the disease.

We identified several immune correlates of clinical disability at the time of lumbar puncture, including those reflecting dysregulated T cell immunity.

First, expanded disability status scale (EDSS) scores and 25-foot walk times (25-FWT) were positively correlated with interleukin 4 (IL-4). Both EDSS and 25-foot walk time reflect ability to ambulate: higher values indicate accruing gross motor disability. IL-4 thus may be a marker of decreased motor function, balance, and stability.

Second, 9-hole PEG test (9-HPT) performance was positively (pathogenically) correlated with CD8a. The 9HPT is an assessment of finger dexterity and fine motor coordination, during which a patient uses one hand to place nine pegs into nine associated holes on a board and subsequently removes them as expeditiously as possible. Test output is time to completion. Thus, higher intrathecal CD8a correlated with slower completion of this task. 9-HPT did not significantly correlate with any other CSF analyte, although did exhibit a positive trend with IL-20RA (p = 0.051, R2 = 0.21).

Third, single digit modalities testing (SDMT) was negatively (pathogenically) correlated with each of the following analytes: CD244 (Natural killer cell receptor 2B4), OPG (Osteoprotegerin), SCF (Stem cell factor), Flt3L (Fms-related tyrosine kinase 3 ligand) and 4E-BP1 (Eukaryotic translation initiation factor 4E-binding protein 1). SDMT is a measure of cognitive processing speed in which a patient is asked to pair numbers and figures within an allotted time limit. A higher score indicates a higher number of successful pairings. Therefore, unlike 9-HPT, EDSS, or 25-FWT, a lower SDMT score indicates poorer performance. SDMT was also negatively correlated with total lesion volume and ventricular size, and positively correlated with thalamic volume, linking brain atrophy with impaired cognitive function.

Interestingly, CSF analytes used for the clinical diagnosis of MS – including oligoclonal band count, IgG index, protein, glucose, and white blood cell count – did not correlate with clinical disability at the time of lumbar puncture.

The findings above underscore the known relevance of T cells in multiple sclerosis. Accumulating evidence in the field of MS has pointed to a role for CD8 + T cells in disease pathogenesis14,15. Indeed, these cells are present in abundance in MS lesions and exhibit TCR affinity for CNS antigens16–19. It is likely that cytotoxic effector cells in the brain mediate damage associated with clinical phenotypes. Contrarily, the exact role of IL-4, a cytokine classically produced by TH2 skewed CD4+ T cells, in MS remains ambiguous. Some studies in the EAE mouse model have indicated that IL-4 may ameliorate disease20,21, though TH2 skewing in other autoimmune diseases can be pathogenic22. IL-4 and IL-4R polymorphisms have been associated with development of MS23,24, though their particular roles remain unclear.

Another proxy for disease progression or severity is compartmental brain atrophy on MRI. In our cohort, brain volumes correlated with several immune analytes. Patients with increased CD8a exhibited smaller thalamic and caudate volumes, adding further evidence to support the role of CD8 T cell immunity in MS. Notably, higher intrathecal interleukin-33 (IL-33) was broadly associated with atrophy, including diminished cortical gray matter, thalamic volume, and caudate volume as well as larger ventricles and greater total lesion volume.

The IL-33/ST-2 axis is widely present in the brain and in circulating immune cells25, is upregulated in MS26, and may hold a pivotal role in regulating various cell lines important in the disease. Indeed, several studies have demonstrated that IL-33 is elevated in the peripheral blood and brain parenchyma of MS patients relative to healthy subjects25,27,28. However, animal models of experimental autoimmune encephalomyelitis (EAE) have revealed conflicting data regarding IL-33’s role in disease progression29–33, and there are opposing findings regarding its effects on myelination26,34. Our results correlate IL-33 with brain atrophy and radiographic disease accumulation. Several hypotheses may be that IL-33 exacerbates disease burden, that it is a protective cytokine upregulated in response to a more severe disease state, or that it is a biproduct of cell injury and death that is inherent to more advanced disease35.

As a pertinent positive control of our volumetric analysis program, our MRI analyses recapitulated the known relationship between aging and gray matter atrophy (Supplemental Fig. 1). These analyses also demonstrated a positive correlation between total volume of T2 hyperintense lesions and ventricular size (a proxy for central brain atrophy). In a multiple linear regression accounting for age, total T2 lesion volume was still an independent predictor of vCSF (p < 0.01, Supplemental Table 3). Thus, our analyses link both age and cumulative disease burden with loss of central brain matter.

We next analyzed the association between age and immune proteins within our cohort. Analytes upregulated in older age may reflect 1. the natural process of aging, 2. an MS-specific process of aging, or alternatively may be markers of 3. milder or later onset disease. Indeed, within our cohort of only DMT-naïve patients, older patients included those who first presented to a physician for MS symptoms later in their lives, as well as those with who had been diagnosed at younger ages but had mild phenotypes not requiring disease modifying therapy. Except for Subject N who presented with fulminant Tumefactive disease and passed away shortly thereafter, no patient over 45 years old in our study required any form of ambulatory assistance (cane, wheelchair, etc.) at the time of sampling.

Age positively correlated with the following immune markers: LIF (Leukemia inhibitor factor), LIFR (Leukemia inhibitory factor receptor), HGF (Hepatocyte growth factor), CASP-8 (Caspase 8), PD-L1 (Programmed cell death 1 ligand 1), IL7 (Interleukin-7), CDCP1 (CUB domain-containing protein 1), TWEAK (Tumor necrosis factor (Ligand) superfamily, member 12), LAP TGF-beta-1 (Latency-associated peptide transforming growth factor beta 1), and OPG (Osteoprotegerin). In contrast IL-13 (Interleukin-13) a type 2 cytokine, was decreased in older patients. Interestingly, LIF/LIFR36–38, HGF39, CASP-840, and PD-L141 all have putative roles in neuroprotection or immunosuppression. Longitudinal sample collection is an important next step to differentiate the physiologic process of aging from potential biomarkers of milder disease.

We then compared immune analytes across sex and disease subtype, both of which are pertinent to clinical disease phenotype.

The relationship between MS phenotype and patient sex is well established, with significant evidence to show that males who develop MS frequently experience more rapid neurologic deterioration42. In our cohort, male MS patients had higher intrathecal FGF-19 (Fibroblast growth factor 19). In a multiple linear regression accounting for age, male sex was still an independent predictor of elevated FGF-19 (p < 0.001). An ROC analysis revealed a sensitivity and specificity of 100% at an FGF-19 NPX cutoff of > 4.691, with AUC of 1.0. Other members of the FGF family of proteins (namely, FGF-1, FGF-2, and FGF-9) have previously been shown to regulate myelination43. Indeed, FGF-9 has been shown to downregulate genes required for axonal transport and synaptic function by neurons in vitro and has thus been proposed as an intrinsic driver of neuronal dysfunction and degeneration independent of inflammation44. Unlike FGF-9, there has been little implication for FGF-19 in MS thus far, however Huang et al. have demonstrated that CSF FGF19 levels in MS patients rise after treatment with Fingolimod13.

On the other hand, females have overall higher susceptibility for developing MS and often exhibit more pronounced inflammatory phenotypes. In our cohort, amongst patients with RRMS, females exhibited greater IL-10RA and IL-20 (Fig. 3B). IL-20 is a part of the IL-10 family of cytokines and has previously been implicated as a pro-inflammatory cytokine in various autoimmune conditions, including psoriasis and rheumatoid arthritis. Dayton et al. suggest a neuroinflammatory and thus pathogenic role for IL-20 signaling in EAE45. IL-10 may exert both pro- and anti-inflammatory functions in MS46.

Finally, we compared analytes across patient disease subtype. Patients whose disease was characterized as Tumefactive expressed higher intrathecal CCL4, a potent chemoattractant, despite a low n of 2. In post-mortem studies of brain tissue, CCL4 is upregulated in Tumefactive demyelinating lesions compared to gliomas47, which often mimic Tumefactive lesions radiologically, and Estevao et al. have proposed that CCL4 increases blood brain barrier permeability and facilitates the transmigration of lymphocytes across endothelial cells48. Of note, one of the two patients with Tumefactive disease in our study passed away shortly after presentation due to fulminant progression. CCL4 may hold a role in fulminant expansion of demyelinating lesions, though a greater number of patients should be assessed in future studies.

Interestingly, we found no intrathecal inflammatory differences between patients with relapsing remitting and progressive disease. This may suggest shared elements of underlying immune pathophysiology of each subtype, despite differences in clinical presentation. It is also possible that analysis of intrathecal proteins is not sensitive enough to capture true immunologic differences between these populations, or that a larger cohort or stricter sample collection during only active relapses is needed to detect them.

Our study has several limitations, including a small sample size, possible selection bias from the lumbar puncture indication, and risk of type I statistical errors. With the exception of our categorical analyses via volcano plot, we did not make attempts to correct for multiple comparisons due to the exploratory nature of this project. Taken together, our data identify potential novel biomarkers that are associated with MS clinical phenotypes and MRI metrics of disease burden. Future studies are needed to validate these biomarkers and test whether they are potential treatment targets and if they have mechanistic involvement in immunopathogenesis.

Materials and methods

Patient selection and clinical samples

This was a retrospective, observational cohort study at a single academic medical center. Inclusion criteria included age 18–65, a diagnosis of MS by 2017 McDonald criteria, and DMT-naïve status at the time of CSF sampling. CSF samples were collected as part of routine clinical care in the UMass Chan Multiple Sclerosis Center. Patients provided written informed consent for storing a portion of CSF in the UMass biorepository. This study was reviewed and approved by the University of Massachusetts ethics board (IRB Protocol 14143). Data collection, storage, and access were in accordance with the Health Insurance Portability and Accountability Act. CSF samples were obtained between 5 years and 8 months prior to this study.

CSF analysis

CSF samples were centrifuged to remove cells and cellular debris and 10uL of the resulting supernatant was shipped in qPCR plates to Olink Proteomics (Cambridge, MA) for analysis using the Olink Target 96 Inflammation Panel (Olink, Boston, MA; Article #95,302) (Fig. 1A). A log-normalized protein expression (NPX or “Normalized Protein eXpression”) file was produced per Olink’s public protocol and utilized for data analysis49. Samples were run on two plates and normalized for comparison via bridging method. Data are available on the Gene Expression Omnibus (GEO) database under accession # GSE256426.

Clinical data

Clinical information for each patient was sourced from the electronic medical record by a medical student or resident, and clinical phenotypes verified by a board-certified neurologist. Patient demographics collected included age, patient-reported race and ethnicity, and sex. Clinical data were collected from the date of the patient’s lumbar puncture, or the nearest date before or after lumbar puncture if not available from the same date. These data included: diagnosis and MS subtype; Expanded Disability Status Scale, timed 25-foot walk, 9-hole peg test, symbol digit modalities test and date and frequency of MS relapses as documented by the patient’s neurologist. Objective metrics used in this study (EDSS, 25-foot walk, 9-hole peg test, SDMT) were obtained within 8 months of initial LP and were only included if they were sustained or worsening over a 6-month period. Patients were classified as either “active” or “inactive” based on evidence of any disease activity within the prior year by NEDA-3 criteria3.

MRI acquisition

All imaging was obtained on 3 T MRI platform (Signa Pioneer, General Electric Healthcare, Wisconsin, USA) using a 32-channel head and neck coil and a consistent acquisition protocol. These sequences consisted of a pre-gadolinium 3D sagittal T1-weighted Fast Gradient Echo (BRAVO) sequence as follows: TR/TE/flip angle = 7.5 ms/3.0 ms/8°, frequency/phase = 220/220, slice thickness = 1.2, FOV = 240 mm; sagittal 3D T2-FLAIR (fluid-attenuated inversion recovery): TR/TE/flip angle/echo train length = 5400/maximum ~ 133/90°/140, frequency/phase = 256/224, slice thickness = 0.8 at 50% resolution, FOV = 250 mm; if gadolinium was administered, an additional sagittal 3D T1-weighted fast spin echo (CUBE) scan was obtained 10 min after gadoterate meglumine infusion as follows: TR/TE/flip angle 435 ms/16.1 ms/90°, frequency/phase = 256/256, slice thickness = 0.6 mm, FOV = 250 mm.

MRI analysis

All T1-weighted scans were manually reviewed for image quality to assure no significant artifacts. Brain masks were obtained using the structural CAT12 pipeline, part of the Statistical Parametric Mapping (SPM, https://www.fil.ion.ucl.ac.uk/spm/) package in Matlab. These masks when then incorporated into the SIENAX tool, a function from the FMRIB software library (FSL, v5.0). SIENAX yields segmented white matter, gray matter, and whole brain tissue volumes, with a normalization multiplicative based on skull registration to a template. FSL FIRST was used to segment subcortical gray matter volumes. T2-hyperintense lesion number and summative volumes (T2LV) were segmented from T2-FLAIR images using the lesion prediction algorithm as implemented in the LST toolbox version 3.0.0 (www.statistical-modelling.de/lst) from SPM with manual adjustment as needed for gross errors in ITK-SNAP v3.8. Only MRIs collected within one year of sample acquisition by lumbar puncture were included in the final analysis.

Data analysis and statistics

Data were analyzed using Olink NPX software, GraphPad Prism software and Microsoft Excel. Bimodal tests were calculated in Olink NPX software for the following parameters: male versus female sex and MS subtypes. For categorical outcomes, statistical thresholds for significance were determined after correcting for multiple comparisons using the Benjamini-Hotchberg method. Clinical metrics (age, EDSS, timed 25-foot walk, 9-hole peg test, SDMT), patient age, and MRI brain tissue segmentation volumes (whole brain, cortical gray matter, whole gray matter, white matter, ventricular CSF as a metric of central brain atrophy, T2-hyperintense lesions, thalamus, and caudate) were analyzed as continuous variables in GraphPad Prism software using correlation analyses. Pearson correlation coefficients and p-values were calculated using Prism.

Supplementary Information

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-67769-1.

Acknowledgements

We thank the patients who donated to the biorepository.

Author contributions

Conceptualization: CI. Methodology: JMR. Software: N/A. Validation: EB, SK, RU, MK, CH, CI. Formal analysis: AR, EB, DAZ, SK, KA, DK, FQ, CH. Investigation: AR, DAZ, KA, FK, IR. Resources: CI, JMR. Sample Acquisition: MD, NF, CI. Data Curation: CI, JMR, CH. Writing- Original Draft: AR, EB, JMR. Writing- Review & Editing: All authors. Visualization: JMR. Supervision: JMR, CI. Project administration: CI, JMR. Funding acquisition: JMR, CI, KA.

Funding

Supported by a SPARK grant from the UMass Center for Clinical and Translational Science, grant # UL1-TR001453 (to KA and JMR) and a grant from the Worcester Foundation for Biomedical Research (to JMR and CI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data availability

The datasets generated for this study can be found in the Gene Expression Omnibus (GEO) Database under accession #GSE256426.

Competing interests

JMR is an inventor on patent application #15/851,651, “Anti111-human CXCR3 antibodies for the Treatment of Vitiligo” which covers targeting CXCR3 for the treatment of vitiligo; and on patent #62489191, “Diagnosis and Treatment of Vitiligo” which covers targeting IL-15 and Trm for the treatment of vitiligo. The remaining authors declare that the research was conducted in the absence of any competing interests that could be construed as a potential conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Alexandra Rabin and Elisa Bello.
==== Refs
References

1. Dobson R Giovannoni G Multiple sclerosis—A review Eur. J. Neurol. 2019 26 27 40 10.1111/ene.13819 30300457
Dobson, R. & Giovannoni, G. Multiple sclerosis—A review. Eur. J. Neurol. 26, 27–40. 10.1111/ene.13819 (2019).30300457
2. Cotsapas C Mitrovic M Erratum: Genome-wide association studies of multiple sclerosis Clin. Transl. Immunol. 2018 7 e1038 10.1002/cti2.1038
Cotsapas, C. & Mitrovic, M. Erratum: Genome-wide association studies of multiple sclerosis. Clin. Transl. Immunol. 7, e1038. 10.1002/cti2.1038 (2018).
3. Lublin FD Defining the clinical course of multiple sclerosis: The 2013 revisions Neurology 2014 83 278 286 10.1212/WNL.0000000000000560 24871874
Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83, 278–286. 10.1212/WNL.0000000000000560 (2014).24871874
4. Solomon AJ The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study Neurology 2016 87 1393 1399 10.1212/WNL.0000000000003152 27581217
Solomon, A. J. et al. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology 87, 1393–1399. 10.1212/WNL.0000000000003152 (2016).27581217
5. Solomon AJ Naismith RT Cross AH Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice Neurology 2019 92 26 33 10.1212/WNL.0000000000006583 30381369
Solomon, A. J., Naismith, R. T. & Cross, A. H. Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice. Neurology 92, 26–33. 10.1212/WNL.0000000000006583 (2019).30381369
6. Filippi M Association between pathological and MRI findings in multiple sclerosis Lancet Neurol. 2012 11 349 360 10.1016/S1474-4422(12)70003-0 22441196
Filippi, M. et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 11, 349–360. 10.1016/S1474-4422(12)70003-0 (2012).22441196
7. Gamraoui S High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis J. Neurol. 2019 266 902 909 10.1007/s00415-019-09212-4 30707357
Gamraoui, S. et al. High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis. J. Neurol. 266, 902–909. 10.1007/s00415-019-09212-4 (2019).30707357
8. Feys P The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis Mult. Scler. 2017 23 711 720 10.1177/1352458517690824 28206826
Feys, P. et al. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult. Scler. 23, 711–720. 10.1177/1352458517690824 (2017).28206826
9. Shaheen HA Sayed SS Daker LI AbdelAziz HE Taha MA Does vitamin D deficiency predict early conversion of clinically isolated syndrome? A preliminary Egyptian study Int. J. Neurosci. 2018 128 946 951 10.1080/00207454.2018.1446954 29493311
Shaheen, H. A., Sayed, S. S., Daker, L. I., AbdelAziz, H. E. & Taha, M. A. Does vitamin D deficiency predict early conversion of clinically isolated syndrome? A preliminary Egyptian study. Int. J. Neurosci. 128, 946–951. 10.1080/00207454.2018.1446954 (2018).29493311
10. Polivka J Polivka J Jr Krakorova K Peterka M Topolcan O Current status of biomarker research in neurology EPMA J. 2016 7 14 10.1186/s13167-016-0063-5 27379174
Polivka, J., Polivka, J. Jr., Krakorova, K., Peterka, M. & Topolcan, O. Current status of biomarker research in neurology. EPMA J. 7, 14. 10.1186/s13167-016-0063-5 (2016).27379174
11. Ziemssen T Kern R Thomas K Multiple sclerosis: Clinical profiling and data collection as prerequisite for personalized medicine approach BMC Neurol. 2016 16 124 10.1186/s12883-016-0639-7 27484848
Ziemssen, T., Kern, R. & Thomas, K. Multiple sclerosis: Clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurol. 16, 124. 10.1186/s12883-016-0639-7 (2016).27484848
12. Cicalini I Integrated lipidomics and metabolomics analysis of tears in multiple sclerosis: An insight into diagnostic potential of lacrimal fluid Int. J. Mol. Sci. 2019 20 1265 10.3390/ijms20061265 30871169
Cicalini, I. et al. Integrated lipidomics and metabolomics analysis of tears in multiple sclerosis: An insight into diagnostic potential of lacrimal fluid. Int. J. Mol. Sci. 20, 1265. 10.3390/ijms20061265 (2019).30871169
13. Huang J Inflammation-related plasma and CSF biomarkers for multiple sclerosis Proc. Natl. Acad. Sci. U. S. A. 2020 117 12952 12960 10.1073/pnas.1912839117 32457139
Huang, J. et al. Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 117, 12952–12960. 10.1073/pnas.1912839117 (2020).32457139
14. Babbe H Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction J. Exp. Med. 2000 192 393 404 10.1084/jem.192.3.393 10934227
Babbe, H. et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192, 393–404. 10.1084/jem.192.3.393 (2000).10934227
15. Mockus TE Munie A Atkinson JR Segal BM Encephalitogenic and regulatory CD8 T cells in multiple sclerosis and its animal models J. Immunol. 2021 206 3 10 10.4049/jimmunol.2000797 33443060
Mockus, T. E., Munie, A., Atkinson, J. R. & Segal, B. M. Encephalitogenic and regulatory CD8 T cells in multiple sclerosis and its animal models. J. Immunol. 206, 3–10. 10.4049/jimmunol.2000797 (2021).33443060
16. Konjevic Sabolek M Communication of CD8(+) T cells with mononuclear phagocytes in multiple sclerosis Ann. Clin. Transl. Neurol. 2019 6 1151 1164 10.1002/acn3.783 31353869
Konjevic Sabolek, M. et al. Communication of CD8(+) T cells with mononuclear phagocytes in multiple sclerosis. Ann. Clin. Transl. Neurol. 6, 1151–1164. 10.1002/acn3.783 (2019).31353869
17. Absinta M A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis Nature 2021 597 709 714 10.1038/s41586-021-03892-7 34497421
Absinta, M. et al. A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis. Nature 597, 709–714. 10.1038/s41586-021-03892-7 (2021).34497421
18. Jingwu Z Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: Precursor frequency, fine specificity, and cytotoxicity Ann. Neurol. 1992 32 330 338 10.1002/ana.410320305 1384421
Jingwu, Z. et al. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: Precursor frequency, fine specificity, and cytotoxicity. Ann. Neurol. 32, 330–338. 10.1002/ana.410320305 (1992).1384421
19. Wagner CA Roque PJ Mileur TR Liggitt D Goverman JM Myelin-specific CD8+ T cells exacerbate brain inflammation in CNS autoimmunity J. Clin. Invest. 2020 130 203 213 10.1172/JCI132531 31573979
Wagner, C. A., Roque, P. J., Mileur, T. R., Liggitt, D. & Goverman, J. M. Myelin-specific CD8+ T cells exacerbate brain inflammation in CNS autoimmunity. J. Clin. Invest. 130, 203–213. 10.1172/JCI132531 (2020).31573979
20. Ponomarev ED Maresz K Tan Y Dittel BN CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells J. Neurosci. 2007 27 10714 10721 10.1523/JNEUROSCI.1922-07.2007 17913905
Ponomarev, E. D., Maresz, K., Tan, Y. & Dittel, B. N. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J. Neurosci. 27, 10714–10721. 10.1523/JNEUROSCI.1922-07.2007 (2007).17913905
21. Ishihara A Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis Nat. Biomed. Eng. 2021 5 387 398 10.1038/s41551-020-00627-3 33046864
Ishihara, A. et al. Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat. Biomed. Eng. 5, 387–398. 10.1038/s41551-020-00627-3 (2021).33046864
22. Haddadi NS Th2 to Th1 transition is required for induction of skin lesions in an inducible and recurrent murine model of cutaneous lupus-like inflammation Front. Immunol. 2022 13 883375 10.3389/fimmu.2022.883375 35833127
Haddadi, N. S. et al. Th2 to Th1 transition is required for induction of skin lesions in an inducible and recurrent murine model of cutaneous lupus-like inflammation. Front. Immunol. 13, 883375. 10.3389/fimmu.2022.883375 (2022).35833127
23. Zhang Z Wang L Sun X Zhang L Lu L Association of IL4 and IL4R polymorphisms with multiple sclerosis susceptibility in Caucasian population: A meta-analysis J. Neurol. Sci. 2016 363 107 113 10.1016/j.jns.2016.02.049 27000232
Zhang, Z., Wang, L., Sun, X., Zhang, L. & Lu, L. Association of IL4 and IL4R polymorphisms with multiple sclerosis susceptibility in Caucasian population: A meta-analysis. J. Neurol. Sci. 363, 107–113. 10.1016/j.jns.2016.02.049 (2016).27000232
24. Qiu LJ Relationship between the IL-4 gene promoter -590C/T (rs2243250) polymorphism and susceptibility to autoimmune diseases: A meta-analysis J. Eur. Acad. Dermatol. Venereol. 2015 29 48 55 10.1111/jdv.12435 24628947
Qiu, L. J. et al. Relationship between the IL-4 gene promoter -590C/T (rs2243250) polymorphism and susceptibility to autoimmune diseases: A meta-analysis. J. Eur. Acad. Dermatol. Venereol. 29, 48–55. 10.1111/jdv.12435 (2015).24628947
25. Christophi GP Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients Clin. Immunol. 2012 142 308 319 10.1016/j.clim.2011.11.007 22189043
Christophi, G. P. et al. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin. Immunol. 142, 308–319. 10.1016/j.clim.2011.11.007 (2012).22189043
26. Allan D Role of IL-33 and ST2 signalling pathway in multiple sclerosis: Expression by oligodendrocytes and inhibition of myelination in central nervous system Acta Neuropathol. Commun. 2016 4 75 10.1186/s40478-016-0344-1 27455844
Allan, D. et al. Role of IL-33 and ST2 signalling pathway in multiple sclerosis: Expression by oligodendrocytes and inhibition of myelination in central nervous system. Acta Neuropathol. Commun. 4, 75. 10.1186/s40478-016-0344-1 (2016).27455844
27. Alsahebfosoul F Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis Biomol. Concepts 2017 8 55 60 10.1515/bmc-2016-0026 28107165
Alsahebfosoul, F. et al. Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis. Biomol. Concepts 8, 55–60. 10.1515/bmc-2016-0026 (2017).28107165
28. Ahmadi M Serum IL-33 level and IL-33, IL1RL1 gene polymorphisms in asthma and multiple sclerosis patients Curr. Mol. Med. 2019 19 357 363 10.2174/1566524019666190405120137 30950351
Ahmadi, M. et al. Serum IL-33 level and IL-33, IL1RL1 gene polymorphisms in asthma and multiple sclerosis patients. Curr. Mol. Med. 19, 357–363. 10.2174/1566524019666190405120137 (2019).30950351
29. Jiang HR IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages Eur. J. Immunol. 2012 42 1804 1814 10.1002/eji.201141947 22585447
Jiang, H. R. et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur. J. Immunol. 42, 1804–1814. 10.1002/eji.201141947 (2012).22585447
30. Milovanovic M Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotype PLoS One 2012 7 e45225 10.1371/journal.pone.0045225 23028861
Milovanovic, M. et al. Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotype. PLoS One 7, e45225. 10.1371/journal.pone.0045225 (2012).23028861
31. Xiao Y Interleukin-33 deficiency exacerbated experimental autoimmune encephalomyelitis with an influence on immune cells and glia cells Mol. Immunol. 2018 101 550 563 10.1016/j.molimm.2018.08.026 30173119
Xiao, Y. et al. Interleukin-33 deficiency exacerbated experimental autoimmune encephalomyelitis with an influence on immune cells and glia cells. Mol. Immunol. 101, 550–563. 10.1016/j.molimm.2018.08.026 (2018).30173119
32. Chen H Interleukin-33 is released in spinal cord and suppresses experimental autoimmune encephalomyelitis in mice Neuroscience 2015 308 157 168 10.1016/j.neuroscience.2015.09.019 26363151
Chen, H. et al. Interleukin-33 is released in spinal cord and suppresses experimental autoimmune encephalomyelitis in mice. Neuroscience 308, 157–168. 10.1016/j.neuroscience.2015.09.019 (2015).26363151
33. Li M Li Y Liu X Gao X Wang Y IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice J. Neuroimmunol. 2012 247 25 31 10.1016/j.jneuroim.2012.03.016 22516472
Li, M., Li, Y., Liu, X., Gao, X. & Wang, Y. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J. Neuroimmunol. 247, 25–31. 10.1016/j.jneuroim.2012.03.016 (2012).22516472
34. Natarajan C Yao SY Sriram S TLR3 agonist poly-IC induces IL-33 and promotes myelin repair PLoS One 2016 11 e0152163 10.1371/journal.pone.0152163 27022724
Natarajan, C., Yao, S. Y. & Sriram, S. TLR3 agonist poly-IC induces IL-33 and promotes myelin repair. PLoS One 11, e0152163. 10.1371/journal.pone.0152163 (2016).27022724
35. Scott IC Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage Sci. Rep. 2018 8 3363 10.1038/s41598-018-21589-2 29463838
Scott, I. C. et al. Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage. Sci. Rep. 8, 3363. 10.1038/s41598-018-21589-2 (2018).29463838
36. Davis SM Pennypacker KR The role of the leukemia inhibitory factor receptor in neuroprotective signaling Pharmacol. Ther. 2018 183 50 57 10.1016/j.pharmthera.2017.08.008 28827150
Davis, S. M. & Pennypacker, K. R. The role of the leukemia inhibitory factor receptor in neuroprotective signaling. Pharmacol. Ther. 183, 50–57. 10.1016/j.pharmthera.2017.08.008 (2018).28827150
37. Gresle MM Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanism PLoS One 2012 7 e47379 10.1371/journal.pone.0047379 23077604
Gresle, M. M. et al. Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanism. PLoS One 7, e47379. 10.1371/journal.pone.0047379 (2012).23077604
38. Hendriks JJ Leukemia inhibitory factor modulates production of inflammatory mediators and myelin phagocytosis by macrophages J. Neuroimmunol. 2008 204 52 57 10.1016/j.jneuroim.2008.07.015 18771807
Hendriks, J. J. et al. Leukemia inhibitory factor modulates production of inflammatory mediators and myelin phagocytosis by macrophages. J. Neuroimmunol. 204, 52–57. 10.1016/j.jneuroim.2008.07.015 (2008).18771807
39. Bai L Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models Nat. Neurosci. 2012 15 862 870 10.1038/nn.3109 22610068
Bai, L. et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 15, 862–870. 10.1038/nn.3109 (2012).22610068
40. Kim S Lu HC Steelman AJ Li J Myeloid caspase-8 restricts RIPK3-dependent proinflammatory IL-1beta production and CD4 T cell activation in autoimmune demyelination Proc. Natl. Acad. Sci. U. S. A. 2022 119 e2117636119 10.1073/pnas.2117636119 35671429
Kim, S., Lu, H. C., Steelman, A. J. & Li, J. Myeloid caspase-8 restricts RIPK3-dependent proinflammatory IL-1beta production and CD4 T cell activation in autoimmune demyelination. Proc. Natl. Acad. Sci. U. S. A. 119, e2117636119. 10.1073/pnas.2117636119 (2022).35671429
41. Linnerbauer M PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation Nat. Commun. 2023 14 5555 10.1038/s41467-023-40982-8 37689786
Linnerbauer, M. et al. PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation. Nat. Commun. 14, 5555. 10.1038/s41467-023-40982-8 (2023).37689786
42. Alvarez-Sanchez N Dunn SE Potential biological contributers to the sex difference in multiple sclerosis progression Front. Immunol. 2023 14 1175874 10.3389/fimmu.2023.1175874 37122747
Alvarez-Sanchez, N. & Dunn, S. E. Potential biological contributers to the sex difference in multiple sclerosis progression. Front. Immunol. 14, 1175874. 10.3389/fimmu.2023.1175874 (2023).37122747
43. Rajendran R Bottiger G Stadelmann C Karnati S Berghoff M FGF/FGFR pathways in multiple sclerosis and in its disease models Cells 2021 10 884 10.3390/cells10040884 33924474
Rajendran, R., Bottiger, G., Stadelmann, C., Karnati, S. & Berghoff, M. FGF/FGFR pathways in multiple sclerosis and in its disease models. Cells 10, 884. 10.3390/cells10040884 (2021).33924474
44. Thummler K Fibroblast growth factor 9 (FGF9)-mediated neurodegeneration: Implications for progressive multiple sclerosis? Neuropathol. Appl. Neurobiol. 2023 49 e12935 10.1111/nan.12935 37705188
Thummler, K. et al. Fibroblast growth factor 9 (FGF9)-mediated neurodegeneration: Implications for progressive multiple sclerosis?. Neuropathol. Appl. Neurobiol. 49, e12935. 10.1111/nan.12935 (2023).37705188
45. Dayton JR Expression of IL-20 Receptor Subunit beta Is Linked to EAE Neuropathology and CNS Neuroinflammation Front Cell Neurosci 2021 15 683687 10.3389/fncel.2021.683687 34557075
Dayton, J. R. et al. Expression of IL-20 Receptor Subunit beta Is Linked to EAE Neuropathology and CNS Neuroinflammation. Front Cell Neurosci 15, 683687. 10.3389/fncel.2021.683687 (2021).34557075
46. Bugbee E Wang AA Gommerman JL Under the influence: Environmental factors as modulators of neuroinflammation through the IL-10/IL-10R axis Front. Immunol. 2023 14 1188750 10.3389/fimmu.2023.1188750 37600781
Bugbee, E., Wang, A. A. & Gommerman, J. L. Under the influence: Environmental factors as modulators of neuroinflammation through the IL-10/IL-10R axis. Front. Immunol. 14, 1188750. 10.3389/fimmu.2023.1188750 (2023).37600781
47. Chen XY Integrative and comparative single-cell analysis reveals transcriptomic difference between human tumefactive demyelinating lesion and glioma Commun. Biol. 2022 5 941 10.1038/s42003-022-03900-0 36085357
Chen, X. Y. et al. Integrative and comparative single-cell analysis reveals transcriptomic difference between human tumefactive demyelinating lesion and glioma. Commun. Biol. 5, 941. 10.1038/s42003-022-03900-0 (2022).36085357
48. Estevao C CCL4 induces inflammatory signalling and barrier disruption in the neurovascular endothelium Brain Behav. Immun. Health 2021 18 100370 10.1016/j.bbih.2021.100370 34755124
Estevao, C. et al. CCL4 induces inflammatory signalling and barrier disruption in the neurovascular endothelium. Brain Behav. Immun. Health 18, 100370. 10.1016/j.bbih.2021.100370 (2021).34755124
49. Assarsson E Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability PLoS One 2014 9 e95192 10.1371/journal.pone.0095192 24755770
Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 9, e95192. 10.1371/journal.pone.0095192 (2014).24755770
